Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

The unit – the first of its kind that Oxford has developed in the Americas – will work on developing new drugs and vaccines to drive ongoing human health research. It will also focus on training a new generation of clinical researchers by offering Master’s, PhD studentships and courses in infectious diseases, clinical development and vaccinology.

The COVID-19 pandemic has brought the risk of life-threatening infectious diseases into sharp focus, and both the University and their Brazilian counterparts initially aim to drive research to better prepare and respond to health risks by focussing on COVID-19 vaccines and treatments before potentially branching out into other clinical areas.

The unit is also a culmination of a strong relationship the University has built with Brazilian researchers during the pandemic.

Professor Sir Andrew Pollard said: 'Brazilian researchers and the public of Brazil made an extraordinary contribution to the clinical trials of the Oxford-AstraZeneca vaccine, with more than 10,000 volunteers taking part. We are delighted to forge stronger links with the local research teams to improve human health under the leadership of Professor Clemens.'

The UK Government supports the establishment of an Oxford-Brazil collaborative centre for research and training in Brazil, while other prestigious institutions such as the University of Siena’s Institute for Global Health and International Vaccines Institute in South Korea are also partners.

Marcelo Queiroga, the Brazilian Minister of Health, said: 'This collaboration between leading Brazilian researchers and the team at the University of Oxford behind the Oxford-AstraZeneca vaccine is a major step forward in ensuring we are better prepared for future health threats and train the next generation of experts across our nations.'

 Article source: https://www.ox.ac.uk/news/2021-11-01-oxford-work-brazil-establish-clinical-research-hub

Similar stories

It’s not just Covid: the triple threat that could overwhelm the NHS this winter - Andrew Pollard

A severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees

Novel all-in-one vaccine developed to tackle future coronavirus threats

Up to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

One billion doses: A moment to celebrate but not a time to be complacent

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.

Severe disease, not mild infection, makes a pandemic – vaccines still offer our best hope

If the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.